What is the difference between SAM and SOM, and why does the distinction matter to investors?

SAM (Serviceable Available Market) narrows the total addressable market down to the segment the company can actually serve given its specific regulatory clearance, geographic footprint, and product indications, while SOM (Serviceable Obtainable Market) further narrows that to the realistic share the company can capture within a defined timeframe given competition and commercial execution constraints. Conflating the two, presenting SAM as if it were an achievable near-term target, is a common pitch mistake that investors will immediately probe by asking what specific penetration assumptions and timeline underlie the number.

What data sources give a MedTech TAM/SAM/SOM model credibility?

Credible models are typically built from claims databases such as CMS Medicare 5 percent or 100 percent files, hospital utilization data from sources like HCUP, clinical registries relevant to the specific specialty, and specialty society procedure volume reports, rather than generalized market research reports with unclear methodology. Sizing must also explicitly account for reimbursement constraints and regulatory-driven addressable subsets, since a device cleared only for a narrow indication cannot realistically address the entire disease population even if the underlying condition is common.

How should TAM/SAM/SOM assumptions change as a MedTech company moves through regulatory milestones?

Before regulatory clearance, SAM should be treated as provisional since it depends on the exact indication for use ultimately granted, which can be narrower or broader than initially planned, and companies should model multiple indication scenarios rather than assuming the broadest possible label. After clearance and as reimbursement coverage is established, the SOM estimate should be revisited using actual early commercial penetration data rather than the pre-launch assumptions used in fundraising materials, since real-world adoption curves in MedTech are often slower than initially modeled due to sales cycle length and provider training requirements.

Back to Founder & Investor Primer

CommercializationHospital Buyer & Reimbursement

TAM / SAM / SOM

Market sizing framework: total, serviceable available, and serviceable obtainable.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

TAM (Total Addressable Market) is the total revenue opportunity if 100% of the market used the product. SAM (Serviceable Available Market) narrows to the segment the company can serve given regulatory, geographic, and product constraints. SOM (Serviceable Obtainable Market) is the realistic share over a defined timeframe. TAM is total demand, SAM is the part a company's product and channels can serve, and SOM is the share it can realistically win. Investors look for clear assumptions on patient counts, procedure volumes and pricing. Overly large TAM figures without a clear path to SOM weaken credibility.

What the regulation says

TAM, SAM and SOM are commercial planning concepts, not market-sizing methods prescribed by MedTech regulation. Regulatory requirements nevertheless constrain the populations, indications and territories a company can credibly include in SAM. Regulation (EU) 2017/745, adopted on 5 April 2017 and generally applicable from 26 May 2021, prohibits misleading device claims in Article 7, including suggestions of uses outside the intended purpose covered by conformity assessment. In the United States, section 502(a) of the Federal Food, Drug, and Cosmetic Act, enacted on 25 June 1938, treats devices with false or misleading labeling as misbranded. Neither provision prescribes a TAM/SAM/SOM calculation. AdvaMed’s Code of Ethics on Interactions with Health Care Professionals, with revisions effective 1 June 2022, provides voluntary guidance for ethical professional interactions, not an official market-sizing methodology or investor-disclosure standard. Its principles should not be presented as a legal requirement to validate market forecasts. For practical planning, distinguish currently authorized markets from opportunities dependent on future authorizations, and disclose assumptions about eligible patients, procedure volumes, pricing, reimbursement and adoption. SOM should identify a timeframe and realistic access constraints. These are analytical safeguards, not regulatory formulas.

What this means in practice

Investors expect bottom-up TAM/SAM/SOM models. In MedTech, sizing must reflect procedure volumes, addressable indications, reimbursement constraints, and competitive dynamics.

Examples

A company developing a novel surgical robot might define its TAM as all surgical procedures globally, its SAM as orthopedic and neurosurgical procedures in the US, and its SOM as 10% of those US procedures within five years.
For a new diagnostic test for a rare disease, the TAM would be all patients with that disease worldwide, the SAM would be patients in countries where the test is approved, and the SOM would be the percentage of those patients the company realistically expects to reach through its sales channels.
A digital health platform for chronic disease management could calculate its TAM as all individuals with the target chronic condition, its SAM as those who are digitally literate and have internet access in its operating regions, and its SOM as the number of users it projects to acquire with its marketing and sales efforts.

Common pitfalls

•Top-down sizing ('1% of a $10B market') without unit economics is a red flag in any pitch.

Frequently asked questions

A top-down estimate assumes the company can capture an arbitrary percentage of a broad market without justifying that assumption against actual procedure volumes, competitive dynamics, or reimbursement constraints, which tells investors nothing about whether the underlying unit economics or go-to-market assumptions are realistic. Investors generally expect a bottom-up model instead, built from incidence or prevalence data, addressable procedure volumes, average selling price, and a defensible penetration curve, so the SOM reflects an achievable near-term outcome rather than an arbitrary market slice.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Commercialization

Bottom-Up Market Sizing

Building market size from procedure volumes × price × penetration.

Founder & Investor Primer

· From this learning path

Regulatory

510(k) Premarket Notification(510(k))

FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.

Adjacent lesson

Commercialization

Freedom to Operate(FTO)

Analysis of whether a product can be sold without infringing third-party IP.

Regulatory

Breakthrough Device Designation(BDD)

FDA program providing expedited review for devices that treat life-threatening or irreversibly debilitating conditions.

Investment & Finance

Capitalization Table(Cap Table)

Ledger of all securities issued by a company and who owns them.

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 4Trade press and expert commentary· 3

Link health: 3 verified· last checked 2026-06-20

a16z·1AdvaMed·1AHRMM·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Commercialization0 / 23

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Commercialization
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Market sizing framework: total, serviceable available, and serviceable obtainable.

·Investors expect bottom-up TAM/SAM/SOM models.
·In MedTech, sizing must reflect procedure volumes, addressable indications, reimbursement constraints, and competitive dynamics.
·SAM (Serviceable Available Market) narrows to the segment the company can serve given regulatory, geographic, and product constraints.

Remember this

Watch out: Top-down sizing ('1% of a $10B market') without unit economics is a red flag in any pitch.

Related terms

Bottom-Up Market Sizing

You may also need

Auto-suggested from Commercialization and shared keywords.

All Commercialization terms